<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335978">
  <stage>Registered</stage>
  <submitdate>19/09/2010</submitdate>
  <approvaldate>1/10/2010</approvaldate>
  <actrnumber>ACTRN12610000823077</actrnumber>
  <trial_identification>
    <studytitle>Novel approaches to improve pain and function in those with sacro-iliac joint dysfunction</studytitle>
    <scientifictitle>Prolotherapy versus placebo injections to improve pain and function in patients with form failure of load transfer of the sacroiliac joint</scientifictitle>
    <utrn>U1111-1117-1011</utrn>
    <trialacronym>prolosij</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>failure of form closure of the sacro-iliac joint</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Injection of 1.0ml of 20% Dextrose in 0.5% Bupivicaine in the dorsal interosseous ligament of the Sacro-Iliac Joint  (SIJ)versus placebo needle. Maximum of six injections. A previous observational trial with three injections (same protocol) yielded good results (Cusi et al, BJSM 2010). The total six injections maximum corresponds to three placebo injections and the cross over three Dextrose injections. Injections are every six weeks. Unblinding after the third injection. If the patient has made adequate improvement no further injections may be required. Six weeks after the third injection unblinding takes place, and cross over takes place at that time.</interventions>
    <comparator>Placebo dry needle in a more superficial plane, without reaching the posterior interosseous ligament of the sacro-iliac joint</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>clinical assessment: Active straight leg raise, palpation of long dorsal sacro-iliac ligament, Stork test and posterior pelvic pain provocation test</outcome>
      <timepoint>Three months post final injection</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pain. Visual Analogue Scale</outcome>
      <timepoint>Three months post final injection</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Functional questionnaires: Quebec Disability Index, Roland Morris 24 and Roland Morris 24 multi,</outcome>
      <timepoint>Three months post final injection</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Patient perception of function. Patient Generated Index</outcome>
      <timepoint>three months post post final injection</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Failure of load transfer not improved with specific lumbopelvic stability exercises</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Infection, fracture, cancer, psychiatric disorders, pregnancy, previous prolotherapy in the same SIJ</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients who fulfil the criteria for diagnosis of failure of load transfer through the sacroiliac joint -history, clinical examination and Single Photon Emission Computerised Tomography - Computed X-ray Tomography (SPECT-CT)- will be asked to participate in this randomised double blind crossover trial. Allocation is concealed by sealed opaque envelopes held by the radiologist who carries out the injections, in a different site to where patients are assessed</concealment>
    <sequence>random number generator where an odd number is placebo and an even number prolotherapy injection. Allocation concealment to be done with sealed envelopes</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>17/09/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Manuel (Mel) Cusi</primarysponsorname>
    <primarysponsoraddress>15 Vernon Street
Strathfield NSW 2135</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Dr Manuel (Mel)  Cusi</fundingname>
      <fundingaddress>160 Belmore Road 
Randwick NSW 2031</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Hans van der Wall</sponsorname>
      <sponsoraddress>4 Hospital Road
Concord West NSW 2138</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Louise Wong</othercollaboratorname>
      <othercollaboratoraddress>4 Hospital Road
Concord West NSW 2138</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients with low back pain who fulfil the diagnostic criteria for deficient load transfer through the sacro-iliac joint (SIJ) (Hungerford et al, 2004; Mens et al, 2001) (sacro-iliac joint dysfunction) and who do not respond to exercise therapy have deficient ligamentous function. 
1. The primary hypothesis of this study is that the injection of 20% Glucose solution into the posterior ligaments of the SIJ will stimulate the formation of new collagen and increase ligament strength.  Tis will be measured by improvement in the following tests: 
a) Stork test (Hungerford et al Spine 2004),
b) Active straight leg raise (ASLR) (Mens et al, 2001 and 2002) ,
c) Posterior pelvic pain provocation test (PPPP) (Ostgaard et al, 1994, Vleeming et al, 2002)
d) Palpation of the long dorsal sacro-iliac ligament (Vleeming at al, 1996)
2. The secondary hypothesis is that the improvement in the ligament function will lead to a decrease in symptoms and an improvement in quality of life measured by 
a) Quebec Back Pain Disability Scale (Kopek et al, 1995) and 
b) Patient Generated Index Questionnaire (PGI) Ruta at al, 1994 Both have been used previously in back pain studies.
The aim of the study is to compare by randomised trial wether CT guided injection of 20% glucose solution into the ligaments of the sacroiliac joint as compared to a sham injection control results in 
a) A negative Stork test
b) A negative ASLR test
c) A negative PPPP test
d) A lower Quebec score
e) Improvement in the PGI, as measured three months after the intervention</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Notre Dame Australia, Sydney Medical School</ethicname>
      <ethicaddress>160 Oxford Street
Darlinghurst NSW 2010</ethicaddress>
      <ethicapprovaldate>3/07/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Australian Institute of Sports Ethics Committee</ethicname>
      <ethicaddress>Australian INstitute of Sport
PO Box 176
Belconnen ACT 2616</ethicaddress>
      <ethicapprovaldate>2/02/2010</ethicapprovaldate>
      <hrec>20091007</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Manuel (Mel) Cusi</name>
      <address>160 Belmore Road
Randwick NSW 2031</address>
      <phone>61-2-93995333</phone>
      <fax />
      <email>m.cusi@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Manuel (Mel) Cusi</name>
      <address>160 Belmore Road
Randwick NSW 2031</address>
      <phone>61-2-9399 5333</phone>
      <fax />
      <email>m.cusi@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Manuel (Mel) Cusi</name>
      <address>160 Belmore Road
Randwick NSW 2031</address>
      <phone>61-2-9399 5333</phone>
      <fax />
      <email>m.cusi@unsw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>